PHILADELPHIA -- Topaz Pharmaceuticals LLC, a pharmaceutical company, announces that the Food and Drug Administration (FDA) has approved an investigational new drug application; allowing Topaz to begin clinical trials of the companys topical solution for the treatment of head lice.
The Topaz product is designed to give healthcare professionals a new choice for the treatment of head lice infestations it will provide a naturally derived treatment that is lethal to lice and nits, yet safe to children and adults. Between 6 and 12 million children are affected by head lice in the
Topaz Pharmaceuticals LLC is a start-up company which initially benefited from support provided by the Ben Franklin Technology Partners of Southeast Pennsylvania, who develops and markets pediatric medicines. The company expects to develop additional indications covering other parasitic insects affecting human health. Topaz Pharmaceuticals is developing a completely novel and kid friendly formulation of a naturally derived, quick-acting ingredient which is lethal to head and body lice.
Source: Topaz Pharmaceuticals, LLC